title: Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
abstract: BACKGROUND
  SOUND-C3 was a multicentre, open-label, phase 2b study exploring the safety and efficacy of the interferon-free combination of faldaprevir (an NS3/A4 protease inhibitor), deleobuvir (BI 207127, a non-nucleoside polymerase inhibitor) and ribavirin in treatment-naive patients with chronic hepatitis C virus (HCV) genotype-1 infection. Results in patients with HCV genotype-1b and in IL28B CC genotype patients with HCV genotype-1a have been described previously. This report describes the results in IL28B non-CC genotype patients with HCV genotype-1a.
  
  
  METHODS
  Patients were randomized to receive faldaprevir 120 mg once daily with deleobuvir at either 800 mg twice daily (b.i.d.; N=26) or 600 mg three times daily (t.i.d.; N=25), and weight-based ribavirin for 24 weeks. The primary endpoint was sustained virological response 12 weeks after treatment (SVR12).
  
  
  RESULTS
  In each group, five patients completed 24 weeks of treatment. SVR12 rates were 19% (5/26) and 8% (2/25) in the b.i.d. and t.i.d. groups, respectively. On-treatment breakthrough [50% (13/26) and 68% (17/25) in the b.i.d. and t.i.d. groups, respectively] was the most frequent reason for not achieving SVR12. Adverse events led to premature treatment discontinuation in six (23%) patients in the b.i.d. group and in two patients (8%) in the t.i.d. group. The majority of adverse events were mild or moderate; the most frequently reported were nausea (67%), fatigue (35%) and diarrhoea (35%).
  
  
  CONCLUSIONS
  In this small study, the interferon-free regimen of faldaprevir, deleobuvir and ribavirin resulted in high rates of virological breakthrough and low rates of SVR12 in IL28B non-CC genotype patients infected with genotype-1a HCV (http://www.clinicaltrials.gov NCT01132313).
authors.affiliation: aJ.W. Goethe University Hospital, Frankfurt am Main bBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach cBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany dThe Liver Institute at Methodist Dallas Medical Center, Dallas eCentral Texas Clinical Research, Austin, Texas fNorthwest Indiana Center for Clinical Research, Valparaiso, Indiana gScripps Clinic, La Jolla, California hBoehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA iHospital Carlos III, Madrid jHospital Universitario Valle de Hebrón and CIBERehd del Instituto Carlos III, Barcelona, Spain kUniversity Clinic for Visceral Surgery and Medicine, University of Bern, Bern, Switzerland lAustin Health, Heidelberg, Victoria, Australia.
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: Parvez
authors.initials: P
authors.lastname: Mantry
authors.forename: Vicente
authors.initials: V
authors.lastname: Soriano
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Buynak
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Dufour
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Pockros
authors.forename: David
authors.initials: D
authors.lastname: Wright
authors.forename: Peter
authors.initials: P
authors.lastname: Angus
authors.forename: Maria
authors.initials: M
authors.lastname: Buti
authors.forename: Jerry O
authors.initials: JO
authors.lastname: Stern
authors.forename: Werner
authors.initials: W
authors.lastname: Kadus
authors.forename: Richard
authors.initials: R
authors.lastname: Vinisko
authors.forename: Wulf
authors.initials: W
authors.lastname: Böcher
authors.forename: Federico J
authors.initials: FJ
authors.lastname: Mensa
mesh_terms: D000179:Acrylates / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000621:Aminoisobutyric Acids; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001315:Australia; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005060:Europe; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000821:virology; D006801:Humans; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D007930:Leucine / Q000031:analogs & derivatives; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage* / Q000009:adverse effects; D010641:Phenotype; D011392:Proline / Q000031:analogs & derivatives; D011480:Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011804:Quinolines; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects; D000072230:Sustained Virologic Response; D013844:Thiazoles / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D000095022:Interferon Lambda
chemical_list: D000179:Acrylates; D000621:Aminoisobutyric Acids; D000998:Antiviral Agents; D001562:Benzimidazoles; D007372:Interferons; D007378:Interleukins; D007930:Leucine; D009842:Oligopeptides; D011392:Proline; D011480:Protease Inhibitors; D011804:Quinolines; D012367:RNA, Viral; D012254:Ribavirin; D013844:Thiazoles; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C000592437:deleobuvir; C552340:faldaprevir